A prospective, single arm clinical study exploring the effectiveness of methylsulfonamide granules in preventing and treating postoperative cough in lung cancer patients

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300079129

Enrollment

Unknown

Registered

2023-12-26

Start date

2024-01-01

Completion date

Unknown

Last updated

2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative cough in lung cancer patients

Interventions

Treatment group:Treatment medication: After lung cancer surgery, 2 bags each time, three times a day, with a treatment period of 4 weeks.

Prevention group:Preventive medication: Starting from 3 days before lung cancer surgery, take 2 bags of metformin granules three times a day. The treatment period is a total of 4 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The patient voluntarily participates in this study with full informed consent and signs a written informed consent form, and agrees to comply with the procedures specified in the study protocol; 2. Age = 18 years old and = 75 years old; 3. Patients with lung cancer confirmed by histology and/or cytology, those who have undergone radical lung cancer surgery or local resection within the past 3 months, and those who continue to cough after surgery, or those who plan to undergo lung cancer surgery within the past 2 weeks; 4. Estimated survival time = 12 weeks; 5. ECOG score: 0-1; 6. The main organ functions meet the following requirements: Platelet count (PLT) = 100 × 109/L; Hemoglobin (HGB) = 90g/L Neutrophil count (NEUT) = 1.5 × 109/L; Creatine clearance rate (CrCl) = 60mL/min; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 5 × Upper limit of normal value (ULN); Total bilirubin (TBIL) = 1.5 × ULN.

Exclusion criteria

Exclusion criteria: 1. Have a history of respiratory infections within 7 days prior to enrollment; 2. Patients with pulmonary lymph node metastasis, peripheral lymph node metastasis, airway metastasis, or possible tumor recurrence; 3. Other researchers believe that it is not suitable to participate in this study.

Design outcomes

Primary

Measure	Time frame
VAS; Days of postoperative cough recovery;Number of cases of postoperative cough;	—

Secondary

Measure	Time frame
Leicester Cough Questionnaire, LCQ;CET;	—

Countries

china

Contacts

Public ContactWeimin Zhang

AnYang Tumor Hospital

494273111@qq.com+86 138 3724 0928

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026